Scottish Medicines Consortium decision on Afinitor® (Everolimus)
The Scottish Medicines Consortium (SMC) has issued a positive recommendation for everolimus, which has been accepted for use in NHS Scotland, as a treatment option for advanced kidney cancer patients who have failed on or after one previous vascular endothelial growth factor (VEGF)-targeted therapy.
Source: Pharmacy Europe - Category: Drugs & Pharmacology Authors: Annabel De Coster Tags: *** Editor's Pick Practical therapeutics Industry News Oncology advanced kidney cancer everolimus Latest News scottish medicines consortium VEGF-targeted therapy Source Type: news
More News: Cancer | Cancer & Oncology | Drugs & Pharmacology | Kidney Cancer | Scotland Health | Urology & Nephrology